Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes

被引：39

作者：

Chambergo-Michilot, Diego ^{[1
,2
]}

Alur, Anish ^{[3
]}

Kulkarni, Saneel ^{[4
]}

Agarwala, Anandita ^{[5
]}

机构：

[1] Univ Cient Sur, Lima, Peru

[2] Torres Salud Natl Res Ctr, Dept Cardiol Res, Lima, Peru

[3] Ridge High Sch, Basking Ridge, NJ USA

[4] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA

[5] Baylor Scott & White Hlth Heart Hosp Baylor Plano, Cardiovasc Div, Plano, TX 75093 USA

来源：

VASCULAR HEALTH AND RISK MANAGEMENT | 2022年 / 18卷

关键词：

mipomersen; familial hypercholesterolemia; apolipoprotein B; B SYNTHESIS INHIBITOR; DENSITY-LIPOPROTEIN CHOLESTEROL; APOLIPOPROTEIN-B; LDL-CHOLESTEROL; ANTISENSE INHIBITOR; DOUBLE-BLIND; EFFICACY; SAFETY;

D O I：

10.2147/VHRM.S191965

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Familial hypercholesterolemia (FH) is an autosomal dominant condition that leads to significantly elevated low-density lipoprotein cholesterol (LDL-C) levels and an elevated risk for cardiovascular disease. Mipomersen is an antisense oligonucleotide inhibitor targeted to apolipoprotein B-100 (apoB-100) mRNA that is administered via subcutaneous injection. Once administered, mipomersen causes selective degradation of the apoB-100 mRNA and inhibition of protein translation. This ultimately results in substantial reductions in LDL-C and other lipoprotein levels. Mipomersen is approved for the treatment of homozygous FH. In this review, we discuss its mechanism, current evidence, limitations of use including adverse events, and impact on health-related quality of life.

引用

页码：73 / 80

页数：8

共 36 条

[1] Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia [J].

Akdim, Fatima ;

Tribble, Diane L. ;

Flaim, JoAnn D. ;

Yu, Rosie ;

Su, John ;

Geary, Richard S. ;

Baker, Brenda F. ;

Fuhr, Rainard ;

Wedel, Mark K. ;

Kastelein, John J. P. .

EUROPEAN HEART JOURNAL, 2011, 32 (21) :2650-2659

[2] Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia [J].

Akdim, Fatima ;

Visser, Maartje E. ;

Tribble, Diane L. ;

Baker, Brenda F. ;

Stroes, Erik S. G. ;

Yu, Rosie ;

Flaim, Joann D. ;

Su, John ;

Stein, Evan A. ;

Kastelein, John J. P. .

AMERICAN JOURNAL OF CARDIOLOGY, 2010, 105 (10) :1413-1419

[3] Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy [J].

Akdim, Fatima ;

Stroes, Erik S. G. ;

Sijbrands, Eric J. G. ;

Tribble, Diane L. ;

Trip, Mieke D. ;

Jukema, J. Wouter ;

Flaim, JoAnn D. ;

Su, John ;

Yu, Rosie ;

Baker, Brenda F. ;

Wedel, Mark K. ;

Kastelein, John J. P. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (15) :1611-1618

[4]

Alonsol R, 2013, EXPERT REV CARDIOVAS, V11, P327, DOI [10.1586/erc.13.7, 10.1586/ERC.13.7]

[5] The Effect of Mipomersen in the Management of Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis of Clinical Trials [J].

Astaneh, Behrooz ;

Makhdami, Nima ;

Astaneh, Vala ;

Guyatt, Gordon .

JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2021, 8 (07)

[6] An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis [J].

Crooke, RM ;

Graham, MJ ;

Lemonidis, KM ;

Whipple, CP ;

Koo, S ;

Perera, RJ .

JOURNAL OF LIPID RESEARCH, 2005, 46 (05) :872-884

[7] Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study [J].

Cuchel, Marina ;

Meagher, Emma A. ;

Theron, Hendrik du Toit ;

Blom, Dirk J. ;

Marais, A. David ;

Hegele, Robert A. ;

Averna, Maurizio R. ;

Sirtori, Cesare R. ;

Shah, Prediman K. ;

Gaudet, Daniel ;

Stefanutti, Claudia ;

Vigna, Giovanni B. ;

Du Plessis, Anna M. E. ;

Propert, Kathleen J. ;

Sasiela, William J. ;

Bloedon, LeAnne T. ;

Rader, Daniel J. .

LANCET, 2013, 381 (9860) :40-46

[8] Autosomal Recessive Hypercholesterolemia Long-Term Cardiovascular Outcomes [J].

D'Erasmo, Laura ;

Minicocci, Ilenia ;

Nicolucci, Antonio ;

Pintus, Paolo ;

Van Lennep, Janine E. Roeters ;

Masana, Luis ;

Mata, Pedro ;

Maria Sanchez-Hernandez, Rosa ;

Prieto-Matos, Pablo ;

Real, Jose T. ;

Ascaso, Juan F. ;

Esteve Lafuente, Eduardo ;

Pocovi, Miguel ;

Fuentes, Francisco J. ;

Muntoni, Sandro ;

Bertolini, Stefano ;

Sirtori, Cesare ;

Calabresi, Laura ;

Pavanello, Chiara ;

Averna, Maurizio ;

Cefalu, Angelo Baldassare ;

Noto, Davide ;

Pacifico, Adolfo Arturo ;

Pes, Giovanni Mario ;

Harada-Shiba, Mariko ;

Manzato, Enzo ;

Zambon, Sabina ;

Zambon, Alberto ;

Vogt, Anja ;

Scardapane, Marco ;

Sjouke, Barbara ;

Fellin, Renato ;

Arca, Marcello .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (03) :279-288

[9] Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy [J].

D'Erasmo, Laura ;

Cefalu, Angelo Baldassare ;

Noto, Davide ;

Giammanco, Antonina ;

Averna, Maurizio ;

Pintus, Paolo ;

Medde, Paolo ;

Vigna, Giovanni Battista ;

Sirtori, Cesare ;

Calabresi, Laura ;

Pavanello, Chiara ;

Bucci, Marco ;

Sabba, Carlo ;

Suppressa, Patrizia ;

Natale, Francesco ;

Calabro, Paolo ;

Sampietro, Tiziana ;

Bigazzi, Federico ;

Sbrana, Francesco ;

Bonomo, Katia ;

Sileo, Fulvio ;

Arca, Marcello .

ADVANCES IN THERAPY, 2017, 34 (05) :1200-1210

[10] Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo-Controlled Study of Healthy Volunteers [J].

Flaim, JoAnn D. ;

Grundy, John S. ;

Baker, Brenda F. ;

McGowan, Mary P. ;

Kastelein, John J. P. .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2014, 3 (02) :e000560

← 1 2 3 4 →